{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:46:24Z","timestamp":1793727984384,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2025ZZTS0194"],"award-info":[{"award-number":["2025ZZTS0194"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170204"],"award-info":[{"award-number":["82170204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011930","name":"Beijing Medical and Health Foundation","doi-asserted-by":"publisher","award":["JSZ021"],"award-info":[{"award-number":["JSZ021"]}],"id":[{"id":"10.13039\/501100011930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04247-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:18:22Z","timestamp":1766060302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies"],"prefix":"10.1007","volume":"75","author":[{"given":"Yi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9024-7522","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"6","key":"4247_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/ajh.26506","volume":"97","author":"M Shi","year":"2022","unstructured":"Shi M, Li L, Wang S et al (2022) Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol 97(6):711\u2013718","journal-title":"Am J Hematol"},{"issue":"1","key":"4247_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K et al (2020) Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 13(1):164","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4247_CR3","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/bjh.19896","volume":"205","author":"E Mirvis","year":"2024","unstructured":"Mirvis E, Benjamin R (2024) Are we there yet? CAR-T therapy in multiple myeloma. Br J Haematol 205(6):2175\u20132189","journal-title":"Br J Haematol"},{"issue":"12","key":"4247_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, Korell F, Porazzi P et al (2023) Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov 22(12):976\u2013995","journal-title":"Nat Rev Drug Discov"},{"key":"4247_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101082","volume":"74","author":"Y Huang","year":"2024","unstructured":"Huang Y, Qin Y, He Y et al (2024) Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updat 74:101082","journal-title":"Drug Resist Updat"},{"issue":"11","key":"4247_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","volume":"16","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto J, Suwa T, Murase Y et al (2020) ARID2 is a pomalidomide-dependent CRL4(CRBN) substrate in multiple myeloma cells. Nat Chem Biol 16(11):1208\u20131217","journal-title":"Nat Chem Biol"},{"issue":"19","key":"4247_CR7","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1182\/bloodadvances.2024013623","volume":"8","author":"P Voorhees","year":"2024","unstructured":"Voorhees P, Suman V, Efebera Y et al (2024) Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse. Blood Adv 8(19):5039\u20135050","journal-title":"Blood Adv"},{"issue":"7","key":"4247_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian C, Meyer B, Labarthe MC et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58(7):1033\u20131045","journal-title":"Cancer Immunol Immunother"},{"key":"4247_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632399","volume":"12","author":"C D'Souza","year":"2021","unstructured":"D\u2019Souza C, Prince HM, Neeson PJ (2021) Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs. Front Immunol 12:632399","journal-title":"Front Immunol"},{"key":"4247_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.reth.2022.05.007","volume":"21","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zu C, Ni F et al (2022) Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement. Regener Ther 21:34\u201336","journal-title":"Regener Ther"},{"issue":"1","key":"4247_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12967-024-05772-w","volume":"22","author":"Y Yan","year":"2024","unstructured":"Yan Y, Tu Y, Cheng Q et al (2024) BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma. J Transl Med 22(1):1087","journal-title":"J Transl Med"},{"issue":"18","key":"4247_CR12","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1182\/bloodadvances.2020002309","volume":"4","author":"IP Foskolou","year":"2020","unstructured":"Foskolou IP, Barbieri L, Vernet A et al (2020) The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome. Blood Adv 4(18):4483\u20134493","journal-title":"Blood Adv"},{"issue":"1","key":"4247_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40164-020-00190-2","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhao P, Huang H (2020) Engineering better chimeric antigen receptor T cells. Exp Hematol Oncol 9(1):34","journal-title":"Exp Hematol Oncol"},{"key":"4247_CR14","first-page":"10","volume":"157","author":"MS Pampusch","year":"2020","unstructured":"Pampusch MS, Skinner PJ (2020) Transduction and expansion of primary T Cells in nine days with maintenance of central memory phenotype. J Vis Exp 157:10\u20133791","journal-title":"J Vis Exp"},{"issue":"3\u20134","key":"4247_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41434-021-00307-0","volume":"30","author":"YI Kim-Hoehamer","year":"2023","unstructured":"Kim-Hoehamer YI, Riberdy JM, Zheng F et al (2023) Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. Gene Ther 30(3\u20134):222\u2013231","journal-title":"Gene Ther"},{"issue":"17","key":"4247_CR16","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","volume":"4","author":"SF Cho","year":"2020","unstructured":"Cho SF, Lin L, Xing L et al (2020) The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv 4(17):4195\u20134207","journal-title":"Blood Adv"},{"issue":"1","key":"4247_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s42003-024-06297-0","volume":"7","author":"SI Takayanagi","year":"2024","unstructured":"Takayanagi SI, Chuganji S, Tanaka M et al (2024) A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism. Commun Biol 7(1):685","journal-title":"Commun Biol"},{"issue":"4","key":"4247_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s13402-023-00833-6","volume":"46","author":"Z Jin","year":"2023","unstructured":"Jin Z, Xiang R, Qing K et al (2023) Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma. Cell Oncol (Dordr) 46(4):1143\u20131157","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"4247_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115940","volume":"5","author":"P Oot\u00e1hal","year":"2016","unstructured":"Oot\u00e1hal P, Pr\u016fkov\u00e1 D, Kr\u00e1l V et al (2016) Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 5(4):e1115940","journal-title":"Oncoimmunology"},{"issue":"16","key":"4247_CR20","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","volume":"11","author":"FJ Hernandez-Ilizaliturri","year":"2005","unstructured":"Hernandez-Ilizaliturri FJ, Reddy N, Holkova B et al (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11(16):5984\u20135992","journal-title":"Clin Cancer Res"},{"issue":"23","key":"4247_CR21","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1158\/0008-5472.CAN-18-1781","volume":"78","author":"Y Fujiwara","year":"2018","unstructured":"Fujiwara Y, Sun Y, Torphy RJ et al (2018) Pomalidomide inhibits PD-L1 induction to promote antitumor immunity. Cancer Res 78(23):6655\u20136665","journal-title":"Cancer Res"},{"issue":"5","key":"4247_CR22","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","volume":"184","author":"ND Mathewson","year":"2021","unstructured":"Mathewson ND, Ashenberg O, Tirosh I et al (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 184(5):1281\u20131298","journal-title":"Cell"},{"issue":"11","key":"4247_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang C, Qiao M et al (2022) Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell 40(11):1407\u20131422","journal-title":"Cancer Cell"},{"issue":"2","key":"4247_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s10120-023-01456-4","volume":"27","author":"C Tsutsumi","year":"2024","unstructured":"Tsutsumi C, Ohuchida K, Katayama N et al (2024) Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer. Gastric Cancer 27(2):248\u2013262","journal-title":"Gastric Cancer"},{"issue":"11","key":"4247_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101803","volume":"5","author":"M Guerrero-Murillo","year":"2024","unstructured":"Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL et al (2024) Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Rep Med 5(11):101803","journal-title":"Cell Rep Med"},{"issue":"2","key":"4247_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA, Ozbay KF, Arkhypov I et al (2024) Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol 21(2):147\u2013164","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4247_CR27","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ (2019) Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16(6):372\u2013385","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"4247_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","volume":"39","author":"GM Delgoffe","year":"2021","unstructured":"Delgoffe GM, Xu C, Mackall CL et al (2021) The role of exhaustion in CAR T cell therapy. Cancer Cell 39(7):885\u2013888","journal-title":"Cancer Cell"},{"issue":"6","key":"4247_CR29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG et al (2014) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN. Br J Haematol 164(6):811\u2013821","journal-title":"Br J Haematol"},{"issue":"7","key":"4247_CR30","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.941742","volume":"3","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Hurst SN, Ebert BL (2014) Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology 3(7):e941742","journal-title":"Oncoimmunology"},{"issue":"26","key":"4247_CR31","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","volume":"125","author":"K Sehgal","year":"2015","unstructured":"Sehgal K, Das R, Zhang L et al (2015) Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 125(26):4042\u20134051","journal-title":"Blood"},{"issue":"11","key":"4247_CR32","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","volume":"71","author":"Y Tian","year":"2022","unstructured":"Tian Y, Wen C, Zhang Z et al (2022) CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy. Cancer Immunol Immunother 71(11):2663\u20132675","journal-title":"Cancer Immunol Immunother"},{"key":"4247_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100615","volume":"20","author":"Y Tang","year":"2023","unstructured":"Tang Y, Yao W, Hang H et al (2023) TGF-\u03b2 blocking combined with photothermal therapy promote tumor targeted migration and long-term antitumor activity of CAR-T cells. Mater Today Bio 20:100615","journal-title":"Mater Today Bio"},{"issue":"2","key":"4247_CR34","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103637","volume":"39","author":"F Wiede","year":"2020","unstructured":"Wiede F, Lu KH, Du X et al (2020) PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. EMBO J 39(2):e103637","journal-title":"EMBO J"},{"issue":"6","key":"4247_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20(6):359\u2013371","journal-title":"Nat Rev Clin Oncol"},{"issue":"29","key":"4247_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh2605","volume":"9","author":"SM Collins","year":"2023","unstructured":"Collins SM, Alexander KA, Lundh S et al (2023) TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells. Sci Adv 9(29):eadh2605","journal-title":"Sci Adv"},{"key":"4247_CR37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Rota G, Kosti P et al (2021) Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20192203","journal-title":"J Exp Med"},{"issue":"1","key":"4247_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J et al (2024) Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J 14(1):213","journal-title":"Blood Cancer J"},{"key":"4247_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215948","volume":"550","author":"B Akbari","year":"2022","unstructured":"Akbari B, Hosseini Z, Shahabinejad P et al (2022) Metabolic and epigenetic orchestration of (CAR) T cell fate and function. Cancer Lett 550:215948","journal-title":"Cancer Lett"},{"key":"4247_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2020.12.004","volume":"500","author":"H Rostamian","year":"2021","unstructured":"Rostamian H, Fallah-Mehrjardi K, Khakpoor-Koosheh M et al (2021) A metabolic switch to memory CAR T cells: implications for cancer treatment. Cancer Lett 500:107\u2013118","journal-title":"Cancer Lett"},{"issue":"1","key":"4247_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12967-021-03165-x","volume":"19","author":"M Zhang","year":"2021","unstructured":"Zhang M, Jin X, Sun R et al (2021) Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J Transl Med 19(1):499","journal-title":"J Transl Med"},{"issue":"21","key":"4247_CR42","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.3390\/cancers14215442","volume":"14","author":"SJ Rial","year":"2022","unstructured":"Rial SJ, V\u00f6lkl S, Aigner M et al (2022) Role of CAR T cell metabolism for therapeutic efficacy. Cancers (Basel) 14(21):5442","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4247_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019connor RS, Fraietta JA et al (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44(2):380\u2013390","journal-title":"Immunity"},{"issue":"2","key":"4247_CR44","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL et al (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30(2):492\u2013500","journal-title":"Leukemia"},{"key":"4247_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693016","volume":"12","author":"JW Fischer","year":"2021","unstructured":"Fischer JW, Bhattarai N (2021) CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol 12:693016","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04247-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04247-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:04:40Z","timestamp":1766066680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04247-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4247"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04247-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6571044\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All human peripheral blood samples were obtained with informed consent and ethical approval from the Third Xiangya Hospital Medical Ethics Committee (Ethics Approval Number: 24767). Animal experiments were conducted in compliance with the guidelines established by Central South University Ethics Committee (Ethics Approval Number: CSU-2024-0042).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"9"}}